Stocktoria

PLUS THERAPEUTICS, INC. PSTV

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-107.82
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$5.2M-$22.4M-$20.8M$4.0M
2024$5.8M-$13.0M-$10.7M-$8.9M
2023$4.9M-$13.3M-$13.0M-$1.3M
2022-$20.3M$6.4M
2021-$13.4M$10.8M
2020-$8.2M$3.0M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Sims Andrew John Hugh MacIntyreChief Financial Officer2026-04-01Option exercise38,323
Sims Andrew John Hugh MacIntyreChief Financial Officer2026-04-01Option exercise29,129
HEDRICK MARC HChief Executive Officer2026-04-01Option exercise159,681
HEDRICK MARC HChief Executive Officer2026-04-01Option exercise201,632

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -107.82 (distress)

  • Working capital / assets 0.175
  • Retained earnings / assets -31.6
  • EBIT / assets -0.937
  • Equity / liabilities 0.324

Source: SEC EDGAR filings · CIK 0001095981 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.